Targeting ERBB2 mutations in solid tumors: biological and clinical implications

Preclinical data have shown that ERBB2 activating mutations are responsive to HER2 tyrosine kinase inhibitors. The aim of this study is to characterize the landscape of ERBB2 mutations in solid tumors and the ...

Source: Journal of Hematology and Oncology - June 25, 2018 Category: Hematology Authors: Sophie Cousin, Emmanuel Khalifa, Amandine Crombe, Yech ’an Laizet, Carlo Lucchesi, Maud Toulmonde, Sylvestre Le Moulec, Céline Auzanneau, Isabelle Soubeyran and Antoine Italiano Tags: Letter to the Editor Source Type: research